FDA Clears New Alzheimer's Blood Test
Roche and Lilly assay could expand earlier diagnosis

The U.S. Food and Drug Administration (FDA) has cleared the Elecsys Phospho-Tau (217P) Plasma test, a blood-based diagnostic developed by Roche Diagnostics with Eli Lilly and Company to help evaluate adults 55 years and older who show signs or symptoms of cognitive impairment. The agency said the test is the first FDA-cleared single-biomarker blood assay designed to both help identify patients likely to have Alzheimer's-related amyloid pathology and help rule out the disease using the same validated clinical cutoffs.
Until now, confirming Alzheimer's disease has generally required either expensive positron emission tomography (PET) brain imaging or analysis of cerebrospinal fluid (CSF) obtained through a lumbar puncture. The new laboratory test measures phosphorylated tau 217 (pTau217) in a patient's blood, providing physicians with another tool to determine whether Alzheimer's disease is the likely cause of cognitive decline. The FDA emphasized that the assay is intended to aid clinical evaluation and should be interpreted alongside a patient's medical history, examination and other diagnostic findings rather than used as a standalone diagnosis.
Roche said the test can be performed on its widely used cobas laboratory analyzers, which are already installed in thousands of hospitals and clinical laboratories, potentially making Alzheimer's biomarker testing more accessible through routine blood collection. The company said major laboratory providers, including Quest Diagnostics and Labcorp, plan to make the test available after the clearance, allowing more patients to be evaluated closer to home instead of traveling to specialized centers.
Health experts say earlier and more accessible diagnosis has become increasingly important as new treatments are approved for patients in the early stages of Alzheimer's disease. By reducing reliance on more invasive or expensive procedures, the blood test could help physicians determine which patients should undergo additional evaluation and whether they may qualify for disease-modifying therapies.